Fig. 7: Antitumor effect of RDPNs@diABZIs-augmented immunotherapy in subcutaneous tumor models. | Nature Communications

Fig. 7: Antitumor effect of RDPNs@diABZIs-augmented immunotherapy in subcutaneous tumor models.

From: Supramolecular polyrotaxane-based nano-theranostics enable cancer-cell stiffening for enhanced T-cell-mediated anticancer immunotherapy

Fig. 7

a Respective bioluminescence images of tumors in mice on day 0, day 5, day 10, and day 15. b, c Individual and average tumor volume curves with indicated treatments. n = 6 biologically independent animals per group. d Survival curves after treatments. n = 6 biologically independent animals per group. e, f Representative flow cytometric analysis and quantification of memory T cells (CD3+CD8+CD44highCD62Llow, gated on CD3+CD8+ T cells) in the spleen. n = 4 biologically independent animals per group, repeated twice. g Survival curves after subcutaneous rechallenge. n = 5 biologically independent samples per group. h, i Bioluminescent images and fluorescence intensity of lung in BALB/C mice. n = 3 biologically independent animals per group. j Relative fluorescence intensity of ex vivo lungs. n = 3 biologically independent animals per group. G1: PBS, G2: NPNs, G3: RDPNs, G4: diABZIs, G5: RDPNs@diABZIs. Data are presented as mean ± s.d. One-way ANOVA with Tukey’s post hoc test (e) or two-tailed Student’s t-test (i, j). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Back to article page